NEW
Pulmicort

Pulmicort

budesonide

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Budesonide
Indications/Uses
Bronchial asthma. Respules: Acute laryngotracheobronchitis (croup) in infants & childn. COPD exacerbations in persons w/o signs of acute resp insufficiency.
Dosage/Direction for Use
Respules Bronchial asthma Adult Initially 1-2 mg bd. Maintenance: 0.5-1 mg bd. Childn Initially 0.5-1 mg bd. Maintenance: 0.25-0.5 mg bd. Acute laryngotracheobronchitis (croup) Infant & childn 2 mg as single dose or 2 1-mg dose separated by 30 min, every 12 hr up to 36 hr or until clinical improvement. COPD exacerbations 4-8 mg daily in 2-4 divided doses. Max: Not >10 days. Turbuhaler Adult 200-800 mcg daily in 2-4 divided doses. Severe cases Up to 1,600 mcg. Childn ≥7 yr 100-800 mcg daily in 2-4 divided doses, 5-7 yr 100-400 mcg daily in 2-4 divided doses.
Contraindications
Special Precautions
Active or quiescent pulmonary TB; fungal or viral resp infections. Pneumonia in patients w/ COPD. Visual disturbances. Hypothalamic-pituitary-adrenal axis suppression, decreased bone mineral density, cataract, glaucoma. Periods of stress, severe asthma attack or elective surgery. Transferring from oral steroids. High-dose & prolonged use. Hepatic impairment. Pregnancy. Growth retardation in childn & adolescents. Respules: Not indicated for rapid relief of bronchospasm. Not suitable as sole therapy for status asthmaticus or other acute asthma exacerbations. Bacterial resp infections. Not to be used w/ +ve pressure delivering systems. Lactation. Turbuhaler: Not intended for rapid relief of acute asthma episodes. Discontinue use if paradoxical bronchospasm occurs. Oral candidiasis. Severe liver cirrhosis. Avoid concomitant use w/ CYP3A4 inhibitors eg, ketoconazole, itraconazole or HIV PIs.
Adverse Reactions
Oral candidiasis; pneumonia (COPD patients); cough; throat irritation. Respules: Hoarseness, sore throat, tongue & mouth irritation, dry mouth. Turbuhaler: Throat candidiasis.
Drug Interactions
Increased systemic exposure w/ CYP3A4 inhibitors eg, ketoconazole, itraconazole. Turbuhaler: Increased plasma conc & corticosteroid effects w/ oestrogens, contraceptive steroids. False results w/ ACTH stimulation test.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03BA02 - budesonide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
Presentation/Packing
Form
Pulmicort respules 0.25 mg/mL
Packing/Price
30 × 1's
Form
Pulmicort respules 0.5 mg/mL
Packing/Price
30 × 1's
Form
Pulmicort turbuhaler 100 mcg/dose
Packing/Price
200 dose x 1's
Form
Pulmicort turbuhaler 200 mcg/dose
Packing/Price
100 dose x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in